Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
AMG Reports Better than Expected First Quarter 2026 Results
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of “Hold” by Brokerages
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update
Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference
What Makes Aura Biosciences (AURA) a New Buy Stock
Permanent Capital Management LP Makes New Investment in Aura Biosciences, Inc. $AURA
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of “Moderate Buy” from Brokerages
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
Incentive Program for the Conversion of BDRs into Shares
Western Exploration Files Amended NI 43-101 Technical Report for the AURA Gold Silver Project
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura Biosciences to Participate in Upcoming Investor Conferences
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
3 Small-Cap Stocks Ready to Deliver Significant Growth
Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +
Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma